Patent details

Basic Information

Publication number:

EP3762026

PCT Application Number:

US2019021034

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP197152804

PCT Publication Number:

WO2019173530

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

USE OF PCSK9 INHIBITOR FOR REDUCING CARDIOVASCULAR RISK

French Title of Invention:

UTILISATION D'INHIBITEUR DE PCSK9 POUR RÉDUIRE LE RISQUE CARDIOVASCULAIRE

German Title of Invention:

VERWENDUNG VON PCSK9 INHIBITOREN ZUR VORBEUGUNG VON HERZ-KREISLAUF-RISIKEN

SPC Number:

Dates

Filing date:

06/03/2019

Grant date:

08/04/2026

EP Publication Date:

13/01/2021

PCT Publication Date:

12/09/2019

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

08/04/2026

EP B1 Publication Date:

08/04/2026

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

06/03/2039

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

01/04/2026

 

 

Name:

Regeneron Pharmaceuticals, Inc.

Address:

777 Old Saw Mill River Road, Tarrytown, NY 10591, United States (US)

Name:

Sanofi Biotechnology

Address:

54 rue La Boétie, 75008 Paris, France (FR)

Inventor

1

Name:

STEG, Philippe

Address:

France (FR)

2

Name:

HANOTIN, Corinne

Address:

France (FR)

3

Name:

SASIELA, William

Address:

United States (US)

4

Name:

PORDY, Robert

Address:

United States (US)

5

Name:

SCHWARTZ, Gregory

Address:

United States (US)

6

Name:

BESSAC, Laurence

Address:

France (FR)

Priority

1

Priority Number:

201862639407 P

Priority Date:

06/03/2018

Priority Country:

United States (US)

2

Priority Number:

201862640361 P

Priority Date:

08/03/2018

Priority Country:

United States (US)

3

Priority Number:

201862641082 P

Priority Date:

09/03/2018

Priority Country:

United States (US)

4

Priority Number:

201862641918 P

Priority Date:

12/03/2018

Priority Country:

United States (US)

5

Priority Number:

201862657495 P

Priority Date:

13/04/2018

Priority Country:

United States (US)

6

Priority Number:

201862683695 P

Priority Date:

12/06/2018

Priority Country:

United States (US)

7

Priority Number:

201862688622 P

Priority Date:

22/06/2018

Priority Country:

United States (US)

8

Priority Number:

201862717530 P

Priority Date:

10/08/2018

Priority Country:

United States (US)

9

Priority Number:

201862736284 P

Priority Date:

25/09/2018

Priority Country:

United States (US)

10

Priority Number:

201862744008 P

Priority Date:

10/10/2018

Priority Country:

United States (US)

11

Priority Number:

201862746319 P

Priority Date:

16/10/2018

Priority Country:

United States (US)

12

Priority Number:

201862770530 P

Priority Date:

21/11/2018

Priority Country:

United States (US)

13

Priority Number:

201862775219 P

Priority Date:

04/12/2018

Priority Country:

United States (US)

14

Priority Number:

201962797680 P

Priority Date:

28/01/2019

Priority Country:

United States (US)

15

Priority Number:

201962802545 P

Priority Date:

07/02/2019

Priority Country:

United States (US)

16

Priority Number:

201962806313 P

Priority Date:

15/02/2019

Priority Country:

United States (US)

17

Priority Number:

19305247

Priority Date:

04/03/2019

Priority Country:

European Patent Office (EPO) (EP)

Classification

IPC classification:

C07K 16/40; A61K 39/00; G01N 33/92; A61P 9/00;

Publication

European Patent Bulletin

Issue number:

202615

Publication date:

08/04/2026

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

31/03/2027

Annual Fee Number:

9

Annual Fee Amount:

115 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages